tbuckley/cabot-search huggingface dataset:
Identification of ABCA5 as a tissue and urine diagnostic marker for prostatic intraepithelial neoplasia (PIN).
Authors: Moriya Shogo, Yasumitsu Moriya, Akira Iyoda, Masaki Takiguchi, Takehiko Fujisawa, Naohiko Seki
Journal: Cancer Research (2006)

5164  Aims: The Wilms’ tumor gene WT1 is originally isolated as a tumor suppressor gene for Wilms’ tumor, a kidney neoplasm of childhood. Recently several reports showed that the WT1 gene was overexpressed in leukemias and some kinds of solid tumors, and its oncogenic role was suggested. In the present study, we examined WT1 expression levels in clinical specimens of non-small cell lung cancer (NSCLC) and estimated the correlation between WT1 expression levels and clinical status. Materials and Methods: Lung cancer tissues and non-cancerous tissues were obtained from patients who had undergone curative resection at Chiba University Hospital. All surgical specimens were collected using informed consent according to institutional guidelines. It consisted 47 NSCLC (15 squamous cell carcinomas, 32 adenocarcinomas) and corresponding adjacent non-cancerous tissues. WT1 expression levels were examined using quantitative real-time RT-PCR. Sequences of primers and probes are as follows: WT1 forward primer 5’-GATAACCACACAACGCCCATC-3’, and reverse primer, 5’-CACACGTCGCACATCCTGAAT-3’; probe, 5’-FAM-ACACCGTGCGTGTGTATTCTGTATTGG-TAMRA-3’; β-actin forward primer, 5’-CCCAGCACAATGAAGATCAAGATCAT-3’ and reverse primer, 5’-ATCTGCTGGAAGGTGGACAGCGA-3’; probe, 5’-FAM-TGAGCGCAAGTACTCCGTGTGGATCGGCG-TAMRA-3’. WT1 expression level of K562 leukemic cells was defined as 1.0. Results: The results of quantitative real-time RT-PCR analysis showed that WT1 gene expression levels were correlated with lymph node metastasis, when a threshold was set at 10x10−3 of WT1 relative expression level. In squamous cell carcinomas, WT1 expression levels of all (8 / 8) patients with lymph node metastasis negative were over 1.0x10−3, however those of only two patients (2/ 7) with lymph node metastasis positive were over 1.0x10−3. WT1 gene was significantly overexpressed in squamous cell carcinoma with lymph node metastasis negative (p=0.016). On the other hand, WT1 expression levels of 4 patients (4/19) with lymph node metastasis negative were expressed over 1.0x10−3 in adenocarcinomas, while those of 9 patients (9/13) with lymph node metastasis positive were expressed over 1.0x10−3. WT1 gene was significantly overexpressed in adenocarcinomas with lymph node metastasis positive (p=0.011). Conclusions: Based on an expression analysis of WT1 gene, we successfully distinguished status of lymph node metastasis in squamous cell carcinoma and adenocarcinoma. These results suggest that WT1 gene expression could be a potential marker for the prediction of lymph node metastasis in NSCLC and WT1 gene is a metastasis-associated gene in NSCLC.
The Alleged Health-Protective Effects of Coffee
Authors: Bibiana García-Bailo, Nanci Guest, Ahmed El-Sohemy
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Megakaryocytes and platelets from a novel human adipose tissue–derived mesenchymal stem cell line
Authors: Keiichi Tozawa, Yukako Ono-Uruga, Masaki Yazawa, Taisuke Mori, Mitsuru Murata, Shinichiro Okamoto, Yasuo Ikeda, Yumiko Matsubara
Journal: Blood (2018)
Ecosystem Traits Linking Functional Traits to Macroecology
Authors: Nianpeng He, Congcong Liu, Shilong Piao, Lawren Sack, Li Xu, Yiqi Luo, Jinsheng He, Xingguo Han, Guangsheng Zhou, Xuhui Zhou, Yi Lin, Qiang Yu, Shirong Liu, Wei Sun, Shuli Niu, Shenggong Li, Jiahui Zhang, Guirui Yu
Journal: Trends in Ecology & Evolution (2018)
Abstract P242: Periodontal Disease and Incident Venous Thromboembolism: the Atherosclerosis Risk in the Community (ARIC) Study
Authors: Logan Cowan, James Pankow, Pamela Lutsey, Kamakshi Lakshminarayan, Aaron Folsom
Journal: Circulation (2017)

Background and Purpose: Previous research has identified an association between periodontal disease (PD) and atherosclerotic cardiovascular disease, but the relationship between PD and venous thromboembolism (VTE) has not been studied. PD may trigger VTE through activating inflammatory, coagulation, and fibrinolysis processes associated with thrombosis. We hypothesize an independent association between PD and increased risk of VTE. Methods: PD was assessed among ARIC participants at visit 4 (1996-1998) using self-reported tooth loss due to gum disease and clinical PD definitions based on ARIC dental exams. PD case definitions from the CDC Periodontal Disease Surveillance workgroup in collaboration with the American Academy of Periodontology (CDC/AAP) and the biofilm-gingival interface (BGI) index were used. The outcome of interest was validated VTE, including all cases of deep vein thrombosis occurring in the leg and pulmonary embolism. Follow- up time was from visit 4 to the first VTE hospitalization, dropping out of the study, death, or else, December 31, 2011. Multivariate-adjusted Cox proportional hazards regression models were used. Results: There were a total of 424 VTE events among the 10,651 ARIC participants who provided baseline self-reported PD data and 314 VTE events among the 8,119 participants who were edentulous at visit 4 or who completed the dental exam from which baseline clinical PD data were obtained. Compared to those without periodontal disease, self-reported history of tooth loss due to gum disease was associated with higher VTE risk (HR = 1.42 (1.11, 1.82)), as was being edentulous at exam 4 [1.51 (1.07, 2.14)] using the CDC/AAP PD definition. No other statistically significant associations were observed between clinical levels of PD and VTE risk. Conclusions: These results suggest that individuals who are edentulous or have experienced tooth loss due to PD may be at higher VTE risk.
Small Molecule Screens Identify CDK8-Inhibitors As Candidate Diamond-Blackfan Anemia Drugs
Authors: Jun Chen, Kavitha Siva, Tomasz Rzymski, Lars Johansson, Thomas Lundbäck, Lorena Nunez Villacis, Fredrik Ek, Bingrui Wang, Amee J George, Yang Wan, Lihong Shi, Melissa IIsley, Agatheeswaran Subramaniam, Mayur Jain, Shubhranshu Debnath, Abdul Ghani Alattar, Hanna Axelsson, Milena Mazan, Eliza Majewska, Ulf R. Tedgard, Marcin W. Wlodarski, Anna-Lena Gustavsson, Roger Olsson, Michal Mikula, Xiaofan Zhu, Krzysztof Brzózka, Ross Hannan, Johan Flygare
Journal: Blood (2018)
Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels
Authors: Romain Capoulade, Calvin Yeang, Kwan L. Chan, Philippe Pibarot, Sotirios Tsimikas
Journal: JAMA Cardiology (2018)

<h3>Importance</h3> Several studies have reported an association of levels of lipoprotein(a) (Lp[a]) and the content of oxidized phospholipids on apolipoprotein B (OxPL-apoB) and apolipoprotein(a) (OxPL-apo[a]) with faster calcific aortic valve stenosis (CAVS) progression. However, whether this association is threshold or linear remains unclear. <h3>Objective</h3> To determine whether the plasma levels of Lp(a), OxPL-apoB, and OxPL-apo(a) have a linear association with a faster rate of CAVS progression. <h3>Design, Setting, and Participants</h3> This secondary analysis of a randomized clinical trial tested the association of baseline plasma levels of Lp(a), OxPL-apoB, and OxPL-apo(a) with the rate of CAVS progression. Participants were included from the ASTRONOMER (Effects of Rosuvastatin on Aortic Stenosis Progression) trial, a multicenter study conducted in 23 Canadian sites designed to test the effect of statin therapy (median follow-up, 3.5 years [interquartile range, 2.9-4.5 years]). Patients with mild to moderate CAVS defined by peak aortic jet velocity ranging from 2.5 to 4.0 m/s were recruited; those with peak aortic jet velocity of less than 2.5 m/s or with an indication for statin therapy were excluded. Data were collected from January 1, 2002, through December 31, 2005, and underwent ad hoc analysis from April 1 through September 1, 2018. <h3>Interventions</h3> After the randomization process, patients were followed up by means of echocardiography for 3 to 5 years. <h3>Main Outcomes and Measures</h3> Progression rate of CAVS as assessed by annualized progression of peak aortic jet velocity. <h3>Results</h3> In this cohort of 220 patients (60.0% male; mean [SD] age, 58 [13] years), a linear association was found between plasma levels of Lp(a) (odds ratio [OR] per 10-mg/dL increase, 1.10; 95% CI, 1.03-1.19;<i>P</i> = .006), OxPL-apoB (OR per 1-nM increase, 1.06; 95% CI, 1.01-1.12;<i>P</i> = .02), and OxPL-apo(a) (OR per 10-nM increase, 1.16; 95% CI, 1.05-1.27;<i>P</i> = .002) and faster CAVS progression, which is marked in younger patients (OR for Lp[a] level per 10-mg/dL increase, 1.19 [95% CI, 1.07-1.33;<i>P</i>= .002]; OR for OxPL-apoB level per 1-nM increase, 1.06 [95% CI, 1.02-1.17;<i>P</i>= .01]; and OR for OxPL-apo[a] level per 10-nM increase, 1.26 [95% CI, 1.10-1.45;<i>P</i>= .001]) and remained statistically significant after comprehensive multivariable adjustment (β coefficient, ≥ 0.25; SE, ≤ 0.004 [<i>P</i>≤ .005]; OR, ≥1.10 [<i>P</i>≤ .007]). <h3>Conclusions and Relevance</h3> This study demonstrates that the association of Lp(a) levels and its content in OxPL with faster CAVS progression is linear, reinforcing the concept that Lp(a) levels should be measured in patients with mild to moderate CAVS to enhance management and risk stratification. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT00800800
Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients
Authors: Elizabeth R. Boskey, Amir H. Taghinia, Oren Ganor
Journal: JAMA Surgery (2018)

A growing number of transgender patients are receiving gender-affirming hormone treatments. It is unclear whether the evidence supports the current practice of routinely discontinuing these hormones prior to surgery.To determine how medications used in cross-sex hormone treatment (CSHT) affect perioperative risk.A series of searches were carried out in PubMed and Excerpta Medica Database to identify articles using each of the terms testosterone, estrogen, estradiol, oral contraceptive, spironolactone, cyproterone acetate, finasteride, dutasteride, leuprolide, goserelin, and histrelin, in combination with the terms surgery, perioperative, thrombosis, thromboembolism, and operative. The search was not restricted to perioperative outcomes in transgender populations because many surgeons routinely discontinue hormone use prior to surgery in this population, which makes it impossible to study how hormones affect outcomes. Additional sources were also identified from the texts of reviewed articles. Articles were excluded if they were animal studies or case reports, did not explicitly discuss surgical outcomes, or were restricted to removal of hormonally sensitive tissues.Eighteen articles addressing perioperative outcomes were identified by this systematic review, including 1 on CSHT, 12 on estrogens and progesterones, 1 on testosterone, and 4 on spironolactone and antiandrogens. Data were limited, but use of exogenous testosterone was not found to be associated with an increased risk of venous thromboembolism or other complications during surgery. Moderate evidence suggests that spironolactone is not associated with negative surgical outcomes. The data linking estrogen use and thrombosis is inconsistent in the perioperative period and does not address the types of estrogens most often used for CSHT.Current evidence does not support routine discontinuation of all CSHT prior to surgery, particularly given the lack of information on risks associated with resuming these medications after they have been stopped. Evidence suggests there is no need to discontinue either testosterone or spironolactone, although their association with perioperative outcome quality has not been studied in depth. Most of the evidence that supports discontinuation of estrogen prior to surgery is based on oral estrogen regimens that are not typically used in transgender patients, and even with those formulations, there are conflicting reports on perioperative risk. Further research is needed to determine the safety of continuing hormone treatment and elucidate risks of short-term discontinuation.
Relationships between distress and sleep in advanced cancer patients and spouse caregivers.
Authors: Maija Reblin, Brian Gonzalez, Richard E Heyman, Lee Ellington, Susan Thomas Vadaparampil
Journal: Journal of Clinical Oncology (2018)

195 Background: Sleep disturbance is a common problem among individuals with advanced cancer. Distress and sleep disturbance are highly interdependent in spouses. Little research has examined dyadic effects of psychological distress on sleep in patient-caregiver spouses, most of whom sleep together. The goal of this study was to determine how anxiety and depression impact one’s own sleep and partner’s sleep in advanced cancer patients and their spouse caregivers. Methods: As part of a larger study, 86 advanced cancer patients and their spouse caregivers completed surveys on demographics and self-reported health, including sleep duration, and the HADS measure of anxiety and depression. A path analysis was conducted to determine the impact of patient and caregiver anxiety and depression on their own and their partner’s sleep. Results: The majority of dyads were white (n = 79) and all were heterosexual. The patient was female in 25 couples. The average age for patients was 67 and 65 for caregivers; couples had been together an average of 35 years. Patients reported sleeping 7.2 hours/night (SD = 1.7) and caregivers reported sleeping 6.72 hours/night (SD = 1.3). Patient and caregiver sleep was significantly correlated (r = .42, p &lt; .01). Controlling for age, sex, and general health, one’s own anxiety was negatively associated with one’s own sleep duration (patient B = -.12, p = .04; caregiver B = -.13, p &lt; .01), but patients’ anxiety was not associated with caregivers’ sleep duration or vice versa. Individuals’ depression was not associated with their own sleep duration, but patient depression was positively associated with caregiver sleep duration (B = .10, p = .05). Conclusions: This is one of the first dyadic explorations of psychological distress and sleep duration in advanced cancer patients and spouse caregivers. The increase in the caregivers’ reported sleep duration associated with patient depression may be an early indicator of caregiver depression. These findings strongly support further research of the dyadic effects of distress on sleep to identify longitudinal effects on holistic sleep outcomes for spouses coping with cancer.
Skin disorders are prominent features in primary immunodeficiency diseases: A systematic overview of current data
Authors: Jill de Wit, Romke J. K. Brada, Joyce van Veldhuizen, Virgil A. S. H. Dalm, Suzanne G. M. A. Pasmans
Journal: Allergy (2018)

Primary immunodeficiency diseases (PIDs) are characterized by an increased risk of infections, autoimmunity, autoinflammation, malignancy, and allergic disorders. Skin disorders are also common clinical features in PIDs and may be among the presenting manifestations. Recognition of specific PID-associated skin conditions in combination with other clinical features as described in the currently used warning signs could raise suspicion of an underlying PID. We aimed to provide a systematically obtained overview of skin disorders and their prevalence in PIDs. Secondary, the prevalence of Staphylococcus (S.) aureus-associated skin disorders and atopy was reviewed, as these are the most prominent skin features in PIDs. A systematic search was performed in EMBASE, MEDLINE, Web of Science, Cochrane, and Google Scholar (up to May 9, 2018). All original observational and experimental human studies that address the presence of skin disorders in PIDs were selected. We rated study quality using the Institute of Health Economics Quality Appraisal Checklist for Case Series Studies. Sixty-seven articles (5030 patients) were included. Study quality ranged from 18.2% to 88.5%. A broad spectrum of skin disorders was reported in 30 PIDs, mostly in single studies with a low number of included patients. An overview of associated PIDs per skin disorder was generated. Data on S. aureus-associated skin disorders and atopy in PIDs were limited. In conclusion, skin disorders are prominent features in PIDs. Through clustering of PIDs per skin disorder, we provide a support tool to use in clinical practice that should raise awareness of PIDs based on presenting skin manifestations.
The association of marital status with suicide among male cancer patients in the United States.
Authors: Nosayaba Osazuwa-Peters, Matthew C Simpson, Aleksandr R Bukatko, Eric Adjei Boakye
Journal: Journal of Clinical Oncology (2018)

181 Background: Suicide rate is among cancer survivors double that of the general United States population, and risk is significantly greater among males than females. Meanwhile, being married confers survival advantage across the cancer continuum, with males benefitting more than females. This study was aimed at determining whether marital status mitigated the risk of suicide among male cancer patients with advanced stage disease. Methods: Male patients with stage IV cancer of nine common cancer sites (prostate, lung/bronchus, colon/rectum, urinary bladder, melanoma of the skin, kidney/renal pelvis, non-Hodgkin lymphoma, head and neck cancer, liver/intrahepatic bile duct) diagnosed from 2007-2015 from the Surveillance, Epidemiology, and End Results 18 database were included. A multivariate competing risks proportional hazards model determined the impact of marital status on suicide while controlling for covariates (age, county-level poverty percentage, insurance status, race/ethnicity, cancer site). This model yielded adjusted hazard ratios (aHR) and 95% confidence intervals (CI). Results: There were 228,627 male patients included, with 330 patients committing suicide. The cohort was predominantly non-Hispanic white (71%), married/partnered (57%), and had an average age of 65 years. In the model including all nine cancer sites, divorced/separated (aHR = 1.92, 95% CI 1.40, 2.62), never married (aHR = 1.98, 95% CI 1.48, 2.66), and widowed patients (aHR = 1.50, 95% CI 1.01, 2.24) were more likely than married/partnered patients to commit suicide. Conclusions: Married cancer survivors with advance stage disease are less likely to die by suicide, highlighting the value of supportive care in cancer survivorship. Unmarried patients with advanced stage disease are candidates for surveillance to mitigate suicide risk.
Communication of prognostic information between oncologists and patients with advanced lung cancer.
Authors: Dilip Sankar Babu, Nicholas Gerbino, Kevin Fiscella, Cleveland Shields, Jennifer J. Griggs, Ronald M. Epstein, Mohamedtaki Abdulaziz Tejani
Journal: Journal of Clinical Oncology (2018)

29 Background: A critical domain of patient-provider communication is helping cancer patients understand their prognosis, as well as the efficacy of treatment options. In this qualitative study, we explored the ways oncology providers approached prognostic discussions during initial office visits with patients with metastatic lung cancer. Methods: Transcripts of initial visits between unannounced standardized patients portraying metastatic non-small cell lung cancer and their oncologists were recorded at multiple practice sites in community and academic settings, as part of a large NIH-funded study. Thematic analysis was conducted on a subset of these recorded visits from one study site. In this secondary analysis, three coders (one medical oncologist, one palliative care physician and one research assistant) reviewed transcripts independently to extract quotes related to prognosis, meeting regularly to review selected quotes and to decide on codes. This process repeated until saturation of themes was achieved (n = 15). Results: Discussions of prognosis were found in all 15 transcripts reviewed. Three main themes were identified: (1) Vagueness, in which best-case/worst-case scenarios were presented without an estimate of life expectancy; (2) Statistical Reliance, in which complex statistical data were presented to the patient; and (3) Emotional Support, in which the discussion was infused with emotional reassurance which was contextually appropriate. A fourth identified theme was (4) Minimizing of Supportive Care, as discussions of management options did not always elaborate on best supportive care. Conclusions: Our qualitative analysis of initial office visits among simulated patients with metastatic lung cancer revealed that providers often frame prognostic information in vague terms without a realistic estimate of life expectancy, sometimes give patients complex statistical data, and tend to accompany their discussions with emotional reassurance. Best supportive care is not always fully explained when management options are reviewed. More work is needed to determine optimal ways to convey prognostic and management information during clinic visits for patients with advanced cancer.